ClinConnect ClinConnect Logo
Search / Trial NCT01273909

Outcomes After Perforator Flap Reconstruction for Breast Reconstruction and/or Lymphedema Treatment

Launched by THE NATIONAL INSTITUTE OF LYMPHOLOGY · Jan 10, 2011

Trial Information

Current as of May 27, 2025

Unknown status

Keywords

Breast Cancer Braca1/2 Genotype Acquired Lymphedema Congenital Lymphedema

ClinConnect Summary

Breast cancer is a serious health issue that affects 1 in 8 women. Although numerous treatments have arisen in recent years to aggressively combat this disease and increase survivorship, many survivors develop a crippling condition that can result in devastating physical and psychological impairments. Breast reconstruction by any method may help recovery psychologically. However, some individuals still report experiencing pain following their recovery from surgery. Additionally, secondary lymphedema is a common yet poorly understood complication of breast cancer patients. For those individu...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Undergoing perforator flap surgery for breast reconstruction and/or vascularized lymph node transfer for treatment of lymphedema
  • Exclusion Criteria:
  • Pregnant
  • unable to read

About The National Institute Of Lymphology

The National Institute of Lymphology is a leading research organization dedicated to advancing the understanding and treatment of lymphatic disorders. With a commitment to innovative clinical trials and collaborative research, the Institute focuses on developing novel therapeutic strategies and improving patient outcomes in lymphatic health. By integrating cutting-edge science with clinical expertise, the National Institute of Lymphology aims to foster breakthroughs in lymphology, enhance public health, and contribute to the global body of knowledge in this specialized field.

Locations

Chicago, Illinois, United States

New Orleans, Louisiana, United States

Charleston, South Carolina, United States

Patients applied

0 patients applied

Trial Officials

Marga F. Massey, M.D.

Principal Investigator

National Institute of Lymphology

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials